References
- MacLennan AH, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2000:CD002978
- Daly E, Gray A, Barlow D, . Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836–40
- Welton AJ, Vickers MR, Kim J, . Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190
- Santen RJ, Allred DC, Ardoin SP, . Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;9(Suppl 1):S1–66
- Sturdee DW, Pines A, on behalf of the IMS Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
- North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17: 242–55
- Hays J, Ockene J, Brunner R, . Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839–54
- Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley M. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Therapy Study (HERS) Trial. JAMA 2002;287:591–7
- Clark JH. A critique of Women's Health Initiative studies (2002–2006). Nuclear Receptor Signalling 2006;4, e023
- Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6:302–10
- Schneider HPG, MacLennan AH, Feeny D. Assessment of health-related quality of life in menopause and aging. Climacteric 2008; 11:93–107
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473–83
- Hunter M. The Women's Health Questionnaire (WHQ): a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45–54
- Schneider HPG, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 2000;3:59–64
- Lopes AA, Latado A, Lopes GB. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2004; 350:622
- Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item Health Survey 1.0. Health Econ 1993;2:217–27
- Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118(Suppl 12B):163–5
- Lindh-Astrand L, Bixo M, Hirschberg AL, . A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010;17:72–9
- Blumel JE, Chedraui P, Baron G, . A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18: 778–85
- Cumming GP, Currie HD, Panay N, Lee AJ. Stopping hormone replacement therapy: were women ill advised? Menopause Int 2011;17:82–7
- Utian W. Quality of life (QOL) in menopause. Maturitas 2007; 57:100–2
- Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. J Br Menopause Soc 2006;12:115–25
- Heller DA, Gold CH, Ahern FM, . Changes in elderly women's health-related quality of life following discontinuation of hormone replacement therapy. BMC Womens Health 2005; 5:7
- Brunner RL, Gass M, Aragaki A, . Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 2005;165: 1976–86